Search This Blog

Monday, July 22, 2019

Glaukos in-licenses Intratus’ drug delivery platform for corneal disorders

Glaukos (NYSE:GKOS) has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.
Financial terms were not disclosed.

Amneal launches generic Lyrica in U.S.

Amneal Pharmaceuticals (NYSE:AMRX) is up 6% premarket after the launchof its generic version of Pfizer’s Lyrica (pregabalin capsules) 25 mg, 50, 75, 100, 150, 200, 225 and 300 mg.
The Company has now launched 21 generic products in 2019.
According to IQVIA, U.S. market sales for year ended May 31, 2019 for pregabalin capsules was ~$5.4B.

Spectrum Pharma expands poziotinib clinical program

Spectrum Pharmaceuticals (NASDAQ:SPPI) is further expanding its poziotinib clinical program by adding three new cohorts in ZENITH20 trial, evaluating the impact of poziotinib treatment on non-small cell lung cancer (NSCLC) patients.
Three new cohorts are currently open to patient enrollment. Cohort 5 includes previously treated or treatment-naïve NSCLC patients with EGFR or HER2 exon 20 insertion mutations.
Cohort 6 includes patients with EGFR mutations who progressed while on treatment with osimertinib and developed an additional EGFR mutation.
Cohort 7 includes patients with a variety of less common mutations in EGFR or HER2 exons 18-21 or the extracellular or transmembrane domains.
Cohorts 1- 4 are each independently powered for a pre-specified statistical hypothesis and the primary endpoint is objective response rate.
Topline results from cohort 1 (previously treated NSCLC patients with EGFR exon 20 insertion mutations) are expected in Q4 2019.

Durect up premarket on Gilead deal

DURECT (NASDAQ:DRRX) is up 39% premarket on light volume in reaction to its out-license agreement with Gilead Sciences (NASDAQ:GILD) granting the latter exclusive global rights to develop and commercialize a long-acting HIV product utilizing its SABER technology.
GILD will also receive exclusive access the SABER platform for HIV and HBV and an exclusive option to in-license additional SABER-based products directed to HIV and HBV.
Under the terms of the deal, GILD will pay DRRX $25M upfront, up to $75M in development and regulatory milestones, up to $70M in sales-based milestones and tiered royalties on net sales. If GILD exercises its option for additional SABER products, it will pay an additional $150M upfront per product plus milestones and tiered royalties on net sales.
The companies will collaborate on specific development activities. GILD will control and fund the development programs.
SABER (Sucrose acetate isobutyrate extended-release) is a technology that enables sustained release of long-acting injectables.

Intec Pharma’s Accordion Pill flunks late-stage Parkinson’s study

Thinly traded nano cap Intec Pharma Ltd. (NASDAQ:NTEC) craters 78% premarket in reaction to its announcement that its Accordion Pill-Carbidopa/Levodopa failed to demonstrate superiority over Merck’s (NYSE:MRKSinemet (Carbidopa-Levodopa) in terms of reduction in daily OFF time in a Phase 3 clinical trial, ACCORDANCE, in Parkinson’s disease patients.
Management will host a conference call this morning at 8:30 am ET to discuss the data.

Premarket analyst action: Bridgebio, Adaptive, Change, Eidos, more

Bridgebio Pharma (NASDAQ:BBIO) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at SVB Leerink. Initiated with Overweight rating and $38 price target at JPMorgan. Initiated with Overweight rating and $50 price target at Piper Jaffray.
Adaptive Biotechnologies (NASDAQ:ADPT) initiated with Buy rating and $47 (22% upside) price target at Guggenheim. Initiated with Neutral rating and $32 price target at Goldman. Initiated with Outperform rating at Cowen and Company. Initiated with Overweight rating at JPMorgan.
Change Healthcare (NASDAQ:CHNG) initiated with Buy rating and $22 (63% upside) price target at Citigroup. Initiated with Buy rating and $20 price target at Goldman. Initiated with Buy rating and $17 price target at Guggenheim. Initiated with Buy rating and $21 price target at SunTrust. Initiated with Market Perform rating at Wells Fargo. Initiated with Outperform rating and $18 price target at Baird. Initiated with Outperform rating and $17 price target at Cowen. Initiated with Outperform rating and $20 price target at SVB Leerink. Initiated with Overweight rating and $18 price target at Barclays. Initiated with Overweight rating and $20 price target at Cantor Fitzgerald. Initiated with Overweight rating and $18 price target at JPMorgan. Initiated with Overweight rating at Piper.
Eidos Therapeutics (NASDAQ:EIDX) initiated with Overweight rating and $55 (58% upside) price target at Piper.
Fate Therapeutics (NASDAQ:FATE) initiated with Overweight rating and $32 (50% upside) price target at Cantor.
McKesson (NYSE:MCK) initiated with Neutral rating and $152 (9% upside) price target at Guggenheim.
Morphic Holding (NASDAQ:MORF) initiated with Buy rating and $27 (70% upside) price target at Jefferies. Initiated with Outperform rating and $30 price target at BMO. Initiated with Outperform rating at Cowen Initiated with Outperform rating and $31 price target at Wells Fargo.
Pluristem Therapeutics (NASDAQ:PSTI) initiated with Buy rating at Ladenburg Thalmann. Shares up 2% premarket.
Translate Bio (NASDAQ:TBIO) initiated with Buy rating and $20 (116% upside) price target at Jefferies.
EHealth (NASDAQ:EHTH) initiated with Outperform rating and $106 (22% upside) price target at First Analysis.
BioLife Solutions (NASDAQ:BLFS) initiated with Buy rating and $23 (31% upside) price target at H.C. Wainwright.
Repligen (NASDAQ:RGEN) initiated with Buy rating and $110 (27% upside) price target at H.C. Wainwright.
Amneal Pharmaceuticals (NYSE:AMRX) upgraded to Outperform at SVB Leerink.

Sunday, July 21, 2019

‘Trojan Horse’ Drug Tricks, Then Kills Cancer Cells

The same tactics used by the ancient Greeks thousands of years ago in battle are being applied by researchers at Northwestern University to fight cancer today. A newly designed drug delivery system is capable of disguising chemotherapeutics as fat, a favorite snack of cancerous tumors, creating an effect likened to the “Trojan horse” tale heralded in Greek lore.
Ever since the ancient Greeks snuck their way into the city of Troy inside a giant wooden horse disguised as a gift, the tale of the Trojan horse has been considered a classic example of strategy and cunning over brute force. Now, researchers are hoping to use a bit of deception in the fight against cancer.
In order to develop this delivery and targeting system, researchers engineered a long-chain fatty acid capable of binding itself to drugs at both ends. The fatty acid, with drugs in tow, is then hidden inside a protein found in human blood that carries fat molecules throughout the body.
Essentially, tumors are “tricked” into inviting the chemotherapeutics inside, allowing the drug to destroy them from the inside out. After making it inside the tumor, the hidden drug activates and kills cancer cells. This innovative delivery method is also lower in toxicity, thus causing less harmful side effects than most other chemotherapy treatments available today.
“It’s like a Trojan horse,” lead researcher Nathan Gianneschi explains in a statement. “It looks like a nice little fatty acid, so the tumor’s receptors see it and invite it in. Then the drug starts getting metabolized and kills the tumor cells.”
In the study, researchers used the new delivery method to carry an FDA-approved chemotherapy drug called paclitaxel into tumors in a small animal model. The drugs entered and completely eliminated tumors carrying bone, pancreatic, and colon cancer.
“It’s like the fatty acid has a hand on both ends: one can grab onto the drug and one can grab onto proteins,” Gianneschi says. “The idea is to disguise drugs as fats so that they get into cells and the body is happy to transport them around.”
Additionally, this new delivery method was able to transport 20 times the dose of paclitaxel typically allowed by two older paclitaxel-based drugs. Amazingly, even with a significantly higher dose, the new Trojan horse method was still found to be 17 times safer than other paclitaxel-based drugs.
“Commonly used small-molecule drugs get into tumors — and other cells,” Gianneschi comments. “They are toxic to tumors but also to humans. Hence, in general, these drugs have horrible side effects. Our goal is to increase the amount that gets into a tumor versus into other cells and tissues. That allows us to dose at much higher quantities without side effects, which kills the tumors faster.”